All In Biotech

Drug Trial Radar · NCT04050215

68GA-PSMA-11 PET/CT Scan in Impacting Treatment Strategies for Patients With Prostate Cancer

Impact of 68GA-PSMA-11 PET/CT on Initial and Subsequent Treatment Strategies of Patients With Prostate Cancer

Last checked: Nov 19, 2026Latest source record: Sep 30, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

937

Actual

Start

Apr 2, 2018

Primary completion

Sep 27, 2021

Study completion Sep 27, 2021

Sponsor

Lead sponsor
Jonsson Comprehensive Cancer CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 8, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II trial studies the impact of 68GA-PSMA-11 positron emission tomography (PET)/computed tomography (CT) scan on treatment strategies for patients with prostate cancer. Diagnostic imaging procedures, such as 68GA-PSMA-11 PET/CT scan, may help doctors plan the best treatment for prostate cancer.

Conditions

  • Biochemically Recurrent Prostate Carcinoma
  • Metastatic Prostate Carcinoma
  • Prostate Adenocarcinoma
  • Prostate Carcinoma
  • PSA Level Greater Than Fifty
  • PSA Progression
  • Stage IV Prostate Cancer AJCC v8
  • Stage IVA Prostate Cancer AJCC v8
  • Stage IVB Prostate Cancer AJCC v8

Interventions

  • Computed TomographyProcedure

    Undergo PET/CT

  • Gallium Ga 68-labeled PSMA-11Drug

    Given IV

  • Positron Emission TomographyProcedure

    Undergo PET/CT

  • Questionnaire AdministrationOther

    Ancillary studies

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Intended and implemented management changes after gallium Ga 68-labeled PSMA-11 (68Ga-PSMA-11) positron emission tomography (PET)/computed tomography (CT)Time frame: Up to 3-6 months after completion of imaging

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • UCLA / Jonsson Comprehensive Cancer Center

    Los Angeles, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.